Investigation into Mersana Therapeutics: Are Shareholders Getting Fair Value? The Ademi Firm is probing Mersana Therapeutics for potential fiduciary duty breaches regarding a financial deal that may not favor public shareholders.

Investigation into Mersana Therapeutics: Are Shareholders Getting Fair Value? #USA #Milwaukee #Ademi_Firm #Mersana_Therapeutics #MRSN

Breaking News: ( NASDAQ: #MRSN ) Expected US Company Earnings on Friday, November 14th, 2025

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results Mersana Therapeutics (NASDAQ: MRSN) announced a definitive merger agreement to be acquired by Day One Biopharmaceuticals for $25.00 per share upfront in cash plus contingent value rights (CVRs) worth up to $30.25 per share, implying total deal value of up to ~$285 million. Closing is expected by the end of January 2026 and is subject to tender and regulatory conditions.Operationally, Mersana reported Q3 2025 cash and equivalents of $56.4M (runway into mid-2026), recognized a $15M milestone from GSK, Q3 collaboration revenue of $11.0M, and a Q3 net loss of $7.5M (or $1.51 per share).

#MRSN Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/MRSN/mersana-therap...

Day One Biopharmaceuticals to Acquire Mersana Therapeutics Mersana Therapeutics (Nasdaq: MRSN) entered into a definitive merger agreement to be acquired by Day One Biopharmaceuticals for $25.00 per share cash upfront plus contingent value rights (CVRs) payable up to $30.25 per share, representing an aggregate deal value of up to approximately $285 million and an equity value of about $129 million at closing. Closing is expected by end of January 2026. The Mersana board unanimously recommends tendering shares; Mersana will become a wholly owned subsidiary and its common stock will be delisted upon closing.

#MRSN Day One Biopharmaceuticals to Acquire Mersana Therapeutics

www.stocktitan.net/news/MRSN/day-one-biopha...

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results Mersana Therapeutics (NASDAQ:MRSN) reported Q2 2025 financial results and provided updates on its clinical programs. The company has enrolled over 45 patients in Emi-Le Phase 1 dose expansion cohorts for triple-negative breast cancer (TNBC). Key financial metrics include $77.0 million in cash and cash equivalents, with a net loss of $24.3 million ($4.87 per share).Notable developments include a $15 million milestone payment from GSK for XMT-2056 development, completion of a 1-for-25 reverse stock split, and regaining Nasdaq compliance. The company expects its current capital to support operations into mid-2026. Initial clinical data from Emi-Le expansion cohorts is planned for release in H2 2025. [ "Achieved $15 million development milestone payment from GSK collaboration", "Successfully regained Nasdaq compliance following reverse stock split", "Strong enrollment with over 45 TNBC patients in Emi-Le Phase 1 expansion cohorts", "Cash runway extended into mid-2026", "Collaboration revenue increased to $3.1M from $2.3M year-over-year", "Reduced G&A expenses by 29% to $7.4M from $10.5M year-over-year" ]

#MRSN Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

www.stocktitan.net/news/MRSN/mersana-therap...

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, has announced a 1-for-25 reverse stock split effective July 25, 2025. The split will reduce outstanding shares from 124.8 million to approximately 5.0 million.The primary goal is to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement. Trading on a split-adjusted basis will begin July 28, 2025, under the same ticker "MRSN". The split won't affect the number of authorized shares or par value, and proportionate adjustments will be made to equity incentive plans. Computershare Trust Company will serve as the exchange agent.

#MRSN Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

www.stocktitan.net/news/MRSN/mersana-therap...

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting Mersana Therapeutics (NASDAQ: MRSN) announced positive interim Phase 1 clinical data for their B7-H4-directed Dolasynthen ADC, Emi-Le (XMT-1660), at ASCO 2025. The drug showed a 31% confirmed objective response rate across B7-H4 high tumors at intermediate doses, and 44% confirmed ORR in patients with ≤4 prior lines of therapy. Notable results include a 56% ORR in ACC-1 patients regardless of dose and B7-H4 expression. The safety profile remained consistent with previous reports, with no new safety signals observed. The trial focused on various cancers including triple-negative breast cancer, HR+/HER2- breast cancer, ovarian cancer, endometrial cancer, and ACC-1. The FDA has granted two Fast Track designations for Emi-Le in advanced/metastatic triple-negative breast cancer and HER2 low/negative breast cancer post-topo-1 ADC treatments.

#MRSN Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

www.stocktitan.net/news/MRSN/mersana-therap...

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Mersana Therapeutics (NASDAQ: MRSN) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug Emi-Le showed promising results in treating cancer patients with B7-H4 high tumors, achieving a 31% objective response rate across tumor types. In triple-negative breast cancer (TNBC) patients with B7-H4 high expression who received prior topo-1 ADC treatment, Emi-Le demonstrated a 29% response rate with median PFS of 16.0 weeks. The company's financial position shows $102.3 million in cash as of March 31, 2025, with runway expected into mid-2026. Q1 2025 resulted in a net loss of $24.1 million ($0.19 per share) compared to $19.3 million in Q1 2024. Mersana plans to report initial expansion cohort data in H2 2025.

#MRSN CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/MRSN/correction-mer...

Clinical Trial Results: Mersana's New Cancer Drug Achieves 31% Response Rate in Hard-to-Treat Tumors Latest ESMO data reveals improved efficacy for Emi-Le in B7-H4 high tumors, with promising survival outcomes in triple-negative breast cancer patients. See full results.

#MRSN Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/MRSN/mersana-therap...

Mersana Slashes Workforce by 55%, Doubles Down on Promising Breast Cancer Drug Pipeline Biotech firm extends cash runway to 2026 through strategic restructuring, prioritizing Emi-Le breast cancer drug development. See full strategic roadmap.

#MRSN Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

www.stocktitan.net/news/MRSN/mersana-therap...

FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 FDA Fast-Tracked Emi-Le demonstrates positive responses in triple-negative breast cancer patients previously treated with ADC therapy. Full efficacy data revealed at ESMO 2025.

#MRSN Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

www.stocktitan.net/news/MRSN/mersana-therap...

#MRSN #마리소년 #COVERSTORY
COOL KIDS NEVER DIE! 동시대의 쿨한 소년들을 위한 스페셜 보이 에디션 ‘마리 소년’의 첫 커버 주인공은 10개의 보석이 모인 #트레저 입니다 💎
2시간 후인 저녁 10시, 특별한 싱글 슈퍼 커버도 공개할 예정이니 조금만 기다려주세요✨❤️‍🔥

#TREASURE

#MRSN #마리소년 #COVERSTORY
COOL KIDS NEVER DIE! 동시대의 쿨한 소년들을 위한 스페셜 보이 에디션 ‘마리 소년’의 첫 커버 주인공은 10개의 보석이 모인 #트레저 입니다 💎
2시간 후인 저녁 10시, 특별한 싱글 슈퍼 커버도 공개할 예정이니 조금만 기다려주세요✨❤️‍🔥

#TREASURE

#MRSN #마리소년 #COVERSTORY
COOL KIDS NEVER DIE! 동시대의 쿨한 소년들을 위한 스페셜 보이 에디션 ‘마리 소년’의 첫 커버 주인공은 10개의 보석이 모인 #트레저 입니다 💎
2시간 후인 저녁 10시, 특별한 싱글 슈퍼 커버도 공개할 예정이니 조금만 기다려주세요✨❤️‍🔥

#TREASURE

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results Mersana Therapeutics (NASDAQ: MRSN) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical development programs. The company announced positive initial Phase 1 data for Emi-Le, its B7-H4-targeting ADC candidate, and received an additional Fast Track designation from the FDA.Key financial metrics for Q4 2024:Cash position: $134.6 million as of December 31, 2024Collaboration revenue: $16.4 million (up from $10.7 million in Q4 2023)Net loss: $14.1 million ($0.11 per share)R&D expenses: $22.3 millionG&A expenses: $8.9 millionFor full year 2024, the company reported collaboration revenue of $40.5 million and a net loss of $69.2 million ($0.56 per share). Mersana expects its current capital resources to support operations into 2026.

#MRSN Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/MRSN/mersana-therap...

FDA Grants Fast Track Status to Mersana's Breast Cancer Drug Emi-Le for Expanded Use Mersana's emiltatug ledadotin receives additional FDA Fast Track designation for treating HER2 low/negative breast cancer, expanding its potential therapeutic reach.

#MRSN Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

www.stocktitan.net/news/MRSN/mersana-therap...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ATOM, #OMER, #SONO, #MRSN, #KLIC

#OptionFlow #OptionsTrading #Trading

NEWS: ( NASDAQ: #MRSN ) Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

#StockMarket #News

Just In: ( NASDAQ: #MRSN ) Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

#StockMarket #News

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CPNG, #MRSN, #BNED, #SO, #CRON

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CPNG 5.9x
2. #PLAY 3.2x
3. #UVIX 3.2x
4. #MRSN 2.8x
5. #CVX 2.3x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GOEV, #ULCC, #COP, #MRSN, #EH

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GOEV 7.7x
2. #TWLO 5.8x
3. #ULCC 4.2x
4. #COP 4.2x
5. #MRSN 4.2x

#OptionFlow #OptionsTrading #Trading